VVT Med's ScleroSafe Gets Peer-Reviewed Validation in Indian Vascular Journal

Apr 30

Holy Spirit Hospital in Mumbai published their numbers, and they’re hard to dispute: 95% vein occlusion at day 30, 100% clinical success across all 30 patients and zero complications at the 90-day follow-up. The study, published in the Indian Journal of Vascular and Endovascular Surgery (Wolters Kluwer Medknow), confirms what VVT has been seeing in commercial deployments: ScleroSafe works, and without the downtime or side effects that come with thermal alternatives. Independent, peer-reviewed data is the gold standard, giving meaningful weight to the NT-NT case. Full article here: https://www.globenewswire.com/news-release/2026/04/30/3284854/0/en/VVT-Med-Announces-Positive-Clinical-Data-for-ScleroSafe-R-Published-in-Peer-Reviewed-Indian-Journal-of-Vascular-and-Endovascular-Surgery.html

VVT Medical

Temima Silver

I3 Capital

Toronto | Miami | Tel Aviv

Securities are offered through Finalis Securities LLC Member FINRA / SIPC. I3 Capital is not a registered broker-dealer, and Finalis Securities LLC and I3 Capital Group Ltd. are separate, unaffiliated entities.

Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)

www.i3-capital.com (the “I3 Capital Website”) is a website operated by I3 Capital Group Ltd.. This website is for informational purposes only; it is not an offer, solicitation, recommendation, or commitment to engage in any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available to residents of certain jurisdictions. Please consult with a Finalis Securities registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and [Insert DBA Name] along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.

Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.

Content on this web site and other I3-branded online content including blogs and social media posts should not be construed as investment advice. I3-Capital receives fees from all companies listed under the “Clients” section of this web site for various services which include any or all of capital markets advisory, investor relations, media advisory and independent editorial content. The opinions expressed in such editorial articles are solely those of the individual writer. Any reliance on the content of these articles is at your sole risk. You should not make any investment decision regarding any content published by I3 Capital without first obtaining advice from a registered investment advisor or other qualified professional.

VVT Med's ScleroSafe Gets Peer-Reviewed Validation in Indian Vascular Journal

VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor

I3 Capital